Series B · Biotech · Cardiff, United Kingdom · Founded 2024 · 11–50 employees
Draig Therapeutics is a clinical-stage biotechnology company developing oral small-molecule therapies for major neuropsychiatric disorders. Spun out of Cardiff University's Medicines Discovery Institute, the firm targets glutamate AMPA and GABA neurotransmitter pathways to restore brain synaptic connectivity. Its lead candidate, DT-101, is an AMPA receptor positive allosteric modulator currently in Phase 2 clinical trials for Major Depressive Disorder. The company secured a $65 million Series B funding round in July 2026 to advance its therapeutic pipeline.
No open roles listed right now.